TABLE 1.
| Total | NTM cohort group | non-NTM control group | |
|---|---|---|---|
| n = 125 | n = 115 | n = 10 | |
| Sex, female | 92 (73.6%) | 88 (76.5%) | 4 (40.0%) |
| Age, years | 75.1 (66.4–82.3) | 74.5 (66.3–82.3) | 79.6 (71.1–82.4) |
| Body mass index, kg/m2 | 19.0 (17.2–20.9) | 18.8 (17.1–20.5) | 22.3 (19.8–23.4) |
| Cavity | 40 (32.0%) | 40 (34.8%) | 0 (0.0%) |
| Elevated ESR (n = 25) | 13/25 (52.0%) | 13/25 (52.0%) | N.A. |
| Anti-GPL-core IgA antibody-positive (n = 62) | 51/62 (82.3%) | 51/62 (82.3%) | N.A. |
| Smoking history | 43 (34.4%) | 36 (31.3%) | 7 (70.0%) |
| Multidrug therapy for mycobacteria at sampling | 44 (35.2%) | 44 (38.2%) | 0 (0.0%) |
| AFB smear-positive | 57 (45.6%) | 57 (49.6%) | 0 (0.0%) |
| AFB culture-positive | 93 (74.4%) | 93 (80.9%) | 0 (0.0%) |
| Pretreatment method | |||
| NALC-NaOH | 54 (43.2%) | 45 (39.1%) | 9 (90.0%) |
| Succinic acid | 71 (56.8%) | 70 (60.9%) | 1 (10.0%) |
a
NTM, nontuberculous mycobacteria; ESR, erythrocyte sedimentation rate; GPL, glycopeptidolipid; IgA, immunoglobulin A; AFB, acid-fast bacilli; NALC-NaOH, N-acetyl-L-cysteine-sodium hydroxide; N.A., not applicable.
b
Data are presented as number (%) or median (interquartile range).